School — Medicine Startups

Arch Oncology Secures $105 Million Series C Financing

View Content

“Arch Oncology’s highly differentiated approach to the development of anti-CD47 agents is a promising development in the immuno-oncology space,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology. “We look forward to continuing to support the Company as it develops and advances its robust pipeline of promising drug candidates, including a broad clinical program for AO-176.”

Print Friendly, PDF & Email

Leave a Reply

Your email address will not be published. Required fields are marked *